To what degree are doctors using filgrastim-sndz (Zarzio) instead of filgrastim (Neupogen) in the US? I suspect many doctors and patients would be reluctant to switch to a non-interchangeable biosimilar, but haven't found any papers studying it's usage here after it's approval last year.